Last reviewed · How we verify
pharmacokinetics
pharmacokinetics is a Biologic drug developed by Centre Hospitalier Universitaire de Saint Etienne. It is currently in Phase 2 development. Also known as: blood sample, Antibiotics, pharmacokintics.
Pharmacokinetics is a branch of pharmacology that studies how the body affects a specific substance after administration, analyzing its chemical metabolism and fate from the moment it enters the body. This field of study is relevant to various substances, including pharmaceutical drugs, such as Quercetin, which has been studied in clinical trials for conditions like XIAP Deficiency.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | pharmacokinetics |
|---|---|
| Also known as | blood sample, Antibiotics, pharmacokintics |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) (PHASE1)
- A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN） (PHASE1)
- Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants (PHASE1)
- A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (PHASE1)
- AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors (PHASE1, PHASE2)
- Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents (PHASE1)
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pharmacokinetics CI brief — competitive landscape report
- pharmacokinetics updates RSS · CI watch RSS
- Centre Hospitalier Universitaire de Saint Etienne portfolio CI
Frequently asked questions about pharmacokinetics
What is pharmacokinetics?
Who makes pharmacokinetics?
Is pharmacokinetics also known as anything else?
What development phase is pharmacokinetics in?
Related
- Manufacturer: Centre Hospitalier Universitaire de Saint Etienne — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: blood sample, Antibiotics, pharmacokintics
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing